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Summary We have investigated the inhibitory effect on experimental or spontaneous lung metastases of
polypeptides which contain repetitive structures of the Arg-Gly-Asp (RGD) or Tyr-Ile-Gly-Ser-Arg (YIGSR)
sequence derived from adhesion molecules, and studied their biological characterisation after administration.
In the spontaneous metastasis model, multiple intravenous (i.v.) administrations of poly (RGD) and poly
(YIGSR) resulted in a reduction of lung tumour colonies, although the monomer peptides, RGD or YIGSR,
had no effect under these conditions. The treatment with poly(RGD) substantially prolonged the survival time
for mice injected i.v. with B16-BL6 cells as compared to the treatment with RGD and random poly(R, G, D).
Tumour cell adhesion to the fibronectin-substrates was remarkably inhibited by adding poly(RGD) freely in
solution. Poly(RGD) was found to inhibit completely the ability of platelets to enhance tumour cell adhesion
to fibronectin-substrate and tumour cell-elicited platelet aggregation in vitro, but poly(R, G, D) had no such
effect. We also found that poly(RGD) led to a decrease in the arrest and retention of tumour cells after its
co-injection with radiolabelled tumour cells and that the radiolabelled polypeptide can be at least decomposed
into small fragments during circulation. Poly(RGD) was found to be still active in inhibiting experimental lung
metastasis even when the contributions of NK cells or macrophages were removed from this system after
pretreatment with anti-asialo GM1 serum, 2-chloroadenosine or carrageenan. The results indicate that the
poly(RGD)-mediated inhibition of tumour metastasis may be due to the interference of the adhesive interac-
tion of tumour cells with a specific site in the target organs. Derivatives of polypeptides which contain RGD
and/or YIGSR sequences derived from cell adhesion proteins may thus provide a promising approach for the
control and prevention of cancer metastasis.
During the metastatic cascade, tumour cells encounter host
cells and/or extracellular matrix and basement membrane
components (Fidler, 1984). As a result of adhesive interac-
tion, this encounter may lead to a multicellular embolus
formation that includes homotypic or heterotypic cell clumps
which can subsequently enhance the survival, arrest and
invasiveness of tumour cells (Terranova et al., 1982, 1984).
Such specific interaction is therefore a fundamental event in
the metastatic process.
Common or characteristic core sequences in cell adhesion
molecules such as fibronectin (Kornblihtt et al., 1985), vit-
ronectin (Suzuki et al., 1985) and laminin (Sasaki et al., 1987;
Sasaki & Yamada, 1987) have been found to contribute to
cell adhesion, and to the spread or migration of cells
(Yamada & Kennedy, 1984; McCarthy & Furcht, 1984;
Humphries et al., 1986). It has been shown that the domain
of fibronectin in cellular recognition is carried by an Arg-
Gly-Asp-Ser (RGDS) sequence. The RGD sequence exists
commonly in many adhesion molecules (Pierschbacher &
Ruoslahti, 1982, 1984). RGD-containing peptides have been
shown to promote cell adhesive capability after their surface
immobilisation, and to inhibit cell adhesion to fibronectin
when added freely in solution (Yamada & Kennedy, 1984,
1987; Hayman et al., 1985; Akiyama & Yamada, 1985).
Humphries et al. (1986, 1988) have recently reported that
Gly-Arg-Gly-Asp-Ser (GRGDS) inhibits experimental meta-
stases when B16-Fl0 melanoma cells are co-injected int-
ravenously (i.v.) into syngeneic mice or mice in which the
platelet function has been impaired by acetylsalicylic acid or
by antiplatelet serum. We synthesised poly(RGD) and
poly(YIGSR) which contain the repetitive structure of RGD
derived from fibronectin and of Tyr-Ile-Gly-Ser-Arg
(YIGSR) from laminin, and found that these polypeptides
inhibit experimental lung metastases more effectively than the
corresponding oligopeptides when co-injected i.v. into mice
with tumour cells (Saiki et al., 1989 b, c; Murata et al., 1989).
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Platelets are known to play an important role in the
regulation of tumour metastasis (Gasic et al., 1973; Jamieson
et al., 1987). Many different types of tumour cell have been
seen to elicit the activation and aggregation of platelets in
vitro (Gasic et al., 1973; Pearlstein et al., 1980). These pro-
perties have been correlated with the metastatic potential of
tumour cells. Various inhibitors of platelet functions have
also been reported to retard tumour metastasis in some
tumour models (Kohga et al., 1981; Mussoni et al., 1978;
Tsuruo et al., 1985). We recently reported that ADP (10-6M)
induced aggregations of human platelets were inhibited by
the pretreatment with poly(RGD) in a concentration-
dependent manner, but were not inhibited by treatment with
poly(R, G, D) in which three amino acids were randomly
arranged and no segment of the RGD sequence was
therefore formed (Saiki et al., 1989 a). On the other hand,
natural killer (NK) cells and macrophages in certain blood
cell populations appear to have an important role in the
destruction of metastatic tumour cells. The activation of
macrophages and NK cells by various immunostimulants led
to the reduction of metastatic colonisation (Herberman,
1984; Hanna, 1985; Fidler et al., 1981).
In this study, we examine the effect of polypeptides con-
taining repetitive structure of the RGD sequence on the lung
metastases of tumour cells, and study their biological charac-
terisation in the metastatic cascade in order to gain insight
into the mechanism and the action of our selected polypep-
tide.
Materials and methods
Mice
Specific pathogen-free mice of the inbred C57BL/6 and
BALB/c strains, female, 7-10-week-old, were purchased
from the Shizuoka Laboratory Animal Centre, Hamamatsu,
Japan. Mice were maintained in the Laboratory of Animal
Experiments, the Institute of Immunological Science, Hok-
kaido University, under laminar air-flow conditions.
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Cells
Highly metastatic Bl 6-BL6 melanoma cells, obtained by an
in vitro selection procedure for invasion (Hart, 1979), were
kindly provided by Dr I.J. Fidler (M.D. Anderson Cancer
Center, Houston, Tx, USA). B16-BL6 melanoma and Lewis
lung carcinoma (3LL) were derived from C57BL/6 mice and
a colon 26 carcinoma was derived from BALB/c mice. These
cells were maintained as monolayer cultures in Eagle's
minimal essential medium (MEM) supplemented with 7.5%
fetal bovine serum (FBS), vitamin solution, sodium pyruvate,
non-essential amino acid and L-glutamine.
Synthetic polypeptide analogues and other reagents
The synthetic polypeptides used in this study and their abb-
reviations (based on the single-letter amino acid code) are
given in Table I. Polypeptides with an Arg-Gly-Asp (RGD)
sequence derived from fibronectin or the Tyr-Ile-Gly-Ser-
Arg (YIGSR) sequence from laminin, as well as their related
analogues, were prepared by the synthesis of the monomer
peptide of the RGD or YIGSR sequences by the conven-
tional method and subsequent polymerisation procedures
with diphenylphosphoryl azide (DPPA), as described
elsewhere (Nishi et al., 1980, 1987). All the amino acids used
in this study were of the L-form. Poly(RGD) or
poly(YIGSR) consist of a sequential structure of the RGD or
YIGSR sequences respectively, whereas poly(R, G, D) con-
sists of a randomly arranged structure of three amino acids.
Hence, in the sequence of poly(RGD), the G residue always
lies between the R and D residues, and the -RGD-
sequence is present as a segment. In the sequence of poly(R,
G, D), on the other hand, three amino acids are randomly
arranged without rule and the probability of their forming
the -RGD- sequence is statistically very small.
Copoly(RGD, K) and copoly(RGD, YIGSR) designate the
polypeptides randomly arranged by RGD tripeptide and
either K or YIGSR respectively, in which -RGD- and/or
-YIGSR- sequences are always present as a segment.
Viscometric measurements and SDS-polyacrylamide gel
electrophoresis showed that the polypeptides were approx-
imately 10 kDa in average molecular weight. They were then
dissolved in Ca2", Mg2 + -free phosphate-buffered saline
(PBS). Purified mouse fibronectin was purchased from the
Seikagaku Kogyo Co. Ltd (Tokyo, Japan). Arg-Gly-Asp-Ser
(RGDS) was purchased from BACHEM Feinchemikauen
AG (Switzerland). Pronase P was obtained from Kaken
Chemicals Co. Ltd (Tokyo, Japan). All reagents and media
used in this study were endotoxin free (approx-
imately < 1.0 ng ml-') as determined by a colorimetric assay
(Pyrodick, Seikagaku Kogyo Co., Tokyo, Japan).
Microassayfor cell adhesion
The adhesion assay was carried out by the method described
previously (Saiki et al., 1986, 1989 b). B16-BL6 melanoma
cells in an exponential growth phase were incubated for 24 h
in MEM containing 5% FBS supplemented with 0.3 yCi ml-'
'25I-iododeoxyuridine (1251-IUdR) (specific activity,
200 mCi mmol-', New England Nuclear, Boston, MA,
USA). The cells were washed twice in warm PBS to remove
unbound radiolabels, harvested by adding 0.02% EDTA in
PBS for 1 min at 37°C and resuspended in cold serum-free
MEM to form a single suspension of cells. '25I-IUdR-labelled
turmour cells (2 x 104) in a volume of 0.05 ml well-' were
added to microculture wells pre-coated with synthetic
polypeptides or fibronectin. The cultures were incubated at
37°C for 20min unless otherwise stated and then washed
four times with PBS to remove unattached cells. The remain-
ing substrate-bound tumour cells were lysed with 0.1 ml of
0.1 N NaOH. The lysate was absorbed by cotton swabs and
monitored for radioactivity by gamma counting. The binding
capacity (no. of cells bound per substrate) was expressed as
follows:
Binding capacity =
c.p.m. of targets bound to substrate
c.p.m. of total tumour cells added
x total number of tumour cells added
Experimental and spontaneous metastases assay
Experimental metastasis was determined by means of tumour
cell injection into the lateral tail veins of mice. Briefly,
tumour cells (5 x 104) were admixed with various concentra-
tions of polypeptides in PBS and immediately 0.2 ml of these
suspensions was injected into the lateral tail vein of syngeneic
mice. The mice were killed 14 days after the inoculation of
the tumour cells. In the spontaneous metastasis assay, mice
were injected subcutaneously with B16-BL6 melanoma cells
(5 x 105) into the right hind footpad. Polypeptides were
administered i.v. on various days after tumour inoculation,
and the primary tumours were surgically removed by
amputation on day 21. Mice were killed 14 days after the
amputation. The lungs were fixed in Bouin's solution and the
lung tumour colonies were counted under a dissecting micro-
scope. The survival time of the animals given i.v. injections
of tumour cells admixed with or without polypeptides was
also determined by allowing the animals to live until they
succumbed naturally from the tumour burden. Animals were
autopsied at the time of death to verify the presence of the
tumour in the lungs. The per cent survivors was calculated as
a function of time.
Platelet aggregation
Blood was obtained from C57BL/6 mice by puncturing the
retro-orbital plexus, using heparin (10 units ml1' in final
concentration) as an anticoagulant. Platelet-rich plasma
(PRP) was prepared by centrifugation at 160 g for 15 min at
room temperature. PRP was adjusted to an appropriate con-
centration with platelet poor plasma (PPP), which had been
prepared by centrifugation at 1,000 g for 10 min. Only plastic
tubes and siliconised microcapillaries were used for these
procedures. Platelet aggregation was measured in a dual
aggregometer Model 440 (Chrono-Log, USA) at 37°C by
constant stirring at 1,000 r.p.m. Variable concentrations of
B16-BL6 tumour cells suspended in PBS were added to
0.25 ml of PRP which was then preincubated both with and
without polypeptides for 5-7 min. The aggregometer was
calibrated with PRP to express 100% optical transmission
and with PPP to express 0% optical transmission.
Organ distribution and retention ofradiolabelled tumour cells
B16-BL6 melanoma cells in the exponential growth phase
were labelled with '25N-IUdR, as described above. '25I-IUdR-
Table I Synthetic polypeptides used in this study
Single-letter
Polypeptide abbreviation
-Arg-Gly-Asp-Arg-Gly-Asp-Arg-Gly-Asp-Arg-Gly-Asp-Arg--- poly(RGD)
---Arg-Gly-Asp-Lys-Lys-Arg-Gly-Asp-Arg-Gly-Asp-Lys-Arg--- copoly(RGD, K)
---Arg-Gly-Asp-Arg-Gly-Asp-Tyr-Ile-Gly-Ser-Arg-Arg-Gly-Asp --- copoly(RGD, YIGSR)
---Tyr-Ile-Gly-Ser-Arg-Tyr-Ile-Gly-Ser-Arg-Tyr-Ile-Gly-Ser --- poly(YIGSR)
---Arg-Asp-Arg-Gly-Asp-GIy-Asp-Asp-Arg-Gly-Gly-Arg-Asp-Gly--- poly(R, G, D)724 I. SAIKI et al.
labelled tumour cells (2 x 104) in a volume of 0.2 ml were
injected i.v. with or without polypeptide into the lateral tail
vein of the C57BL/6 mice. Mice were exsanguinated at times
ranging from 30 min to 24 h after the injection. The lungs,
liver, spleen, kidneys and blood were collected from each
mouse, and rinsed in 70% ethanol. The radioactivity in each
organ was measured in a gamma counter.
Labelling ofsynthetic polypeptide
Copoly (RGD, K) was iodinated with Bolton-Hunter reagent
according to the conventional procedure. Briefly, 2 mg
copoly(RGD, K) was dissolved in 20pl PBS and added to
1 mCi Bolton-Hunter reagent (N-succinimidyl 3-(4 hydroxy-
3,5-'25I-diiodophenyl) propionate, specific activity
2,000 Ci mmol ', New England Nuclear, Boston, MA, USA)
freshly dried from a solution in benzene. After agitation of
the mixture at 4°C overnight, the reaction was quenched by
the addition of 5pil 1 M glycine in a borate buffer. lodinated
polypeptide was separated from the byproducts by gel filtra-
tion on a Sephadex G-25 which was equilibrated and eluted
with a 0.05 M phosphate buffer (pH 7.5) containing 0.25%
(w/v) gelatin. The '25I-labelled polypeptide thus obtained was
confirmed by the absorbence at 280 nm in a spect-
rophotometer.
Statistical analysis
The statistical significance of differences between the groups
was determined by applying Student's two-tailed t test unless
otherwise mentioned.
Results
Inhibition ofspontaneous and experimental lung metastases by
polypeptides
We first examined the effect of polypeptides containing the
RGD and/or YIGSR sequence on lung metastasis of B16-
BL6 melanoma in the spontaneous metastasis model (Table
II). Multiple i.v. administrations of 100,.g poly(RGD),
poly(YIGSR) or copoly(RGD, YIGSR) significantly reduced
the number of lung tumour colonies (P <0.01, 0.05 or 0.001
respectively). Copoly(RGD, YIGSR), in which the RGD and
YIGSR sequences were randomly arranged at a 1:1 molar
ratio, inhibited tumour metastasis more effectively than either
poly(RGD) or poly(YIGSR). We also observed that polypep-
tides containing RGD sequence inhibited the experimental
lung metastases after i.v. co-injection with different original
metastatic tumour cells such as B16-BL6 melanoma, 3LL
carcinoma and colon 26 carcinoma, but poly(R, G, D),
which is a random homologue of poly(RGD), did not (Saiki
et al., 1989 b, c). The survival rate of mice given i.v. injec-
tions of B16-BL6 melanoma cells admixed with poly(RGD),
Table II Effect ofpolypeptides on spontaneous lung metastases by an
intra-footpad injection of BI6-BL6 melanoma
No. oflung metastases
Dose (j.g on day 35
Administered i.v. with per mouse) mean ± s.d. (range) pa
Untreated (PBS) - 66 ± 18 (34- 80)
Poly(RGD) 100 36 ± 8 (30- 46) <0.01
Poly(YIGSR) 100 28 ± 24 (12- 64) <0.05
Copoly(RGD, YIGSR) 100 12 ± 8 ( 2- 18) <0.001
RGD 100 54 ± 22 (38- 90)
YIGSR 100 60 ± 38 (20- 116)
Five C57BL/6 mice per group were administered i.v. with polypep-
tides on days 7, 9, 11, 13, 15, 17 and 19 after tumour inoculation.
Primary tumours were surgically removed on day 21 and mice were
sacrificed 2weeks after tumourexcision. aCompared with thecontrol by
Student's two-tailed t test.
poly(R, G, D) or RGD tripeptide was also determined
(Figure 1). In this experiment, 50% of the mice which
received untreated tumour cells succumbed to the tumour
burden within 25 days of the injection. Similar survival rates
were observed in the group of mice which received B16-BL6
cells admixed with poly(R, G, D) or RGD. The group that
received tumour cells together with poly(RGD) showed a
significantly enhanced survival rate (P <0.01 by
Mann-Whitney U probability test), but virtually all the mice
had succumbed within 50 days of the i.v. injection of the
tumour cells.
Effect ofanti-asialo GMJ serum, 2-chloroadenosine and
carrageenan onpoly(RGD)-mediated inhibition oftumour
metastasis
Since NK cells or macrophages in the circulation play an
important.role in the inhibition of tumour metastasis, we
investigated whether or not poly(RGD) can stimulate NK
cells or macrophages to induce the inhibition of tumour
metastasis. Anti-asialo GMI serum can selectively eliminate
NK cells (Habu et al., 1981) and 2-chloroadenosine (Saito &
Yamaguchi, 1985), and carrageenan were macrophage toxic
substances. Table III shows that the pretreatments with anti-
asialo GM1 serum, 2-chloroadenosine or carrageenan
enhanced the frequency of experimental metastasis as com-
pared with the frequency found among untreated normal
mice. The co-injection with poly(RGD) led to a significant
reduction of lung tumour colonies in both untreated and
treated mice.
Effect ofpoly (RGD) on the interaction between tumour cells
andplatelets
Several investigators have reported that platelets play an
important role in the regulation of metastatic seeding. We
therefore examined the effect of platelets and/or poly(RGD)
on tumour cell adhesion to fibronectin-coated substrates.
Figure 2 shows that B16-BL6 cells attached themselves to the
fibronectin-coated substrate, but poly(RGD) led to a
significant inhibition of tumour cell-adhesion to the substrate
(P <0.001). On the other hand, PRP dramatically enhanced
the adhesion of B16-BL6 cells to the fibronectin-substrate in
an assay on only 10 min, whereas PPP did not. The enhanced
adhesion of tumour cells in the presence of PRP was
dramatically inhibited by the addition of poly(RGD). These
results indicate that poly(RGD) is able to inhibit the
adhesion of tumour cells to immobilised fibronectin, as well
as cell adhesion enhanced by platelets. We also investigated
the effect of poly(RGD) on the platelet aggregation induced
by tumour cells in vitro. Platelet aggregation elicited by B16-
BL6 cells was monitored by a dual aggregometer (Figure 3).
Poly(RGD) at a concentration of 100tgml-' inhibited the
platelet aggregation induced by B16-BL6 cells. In contrast,
16
Cn
-o
Days after tumour inoculation
Figure I Effect of i.v. administration of polypeptides on the
survival of C57BL/6 mice injected with B16-BL6 melanoma cells.
Mice were injected i.v. with B16-BL6 cells (5 x 104) together with
medium (0 0), poly(RGD) (@-0), RGD (o-o) or poly
(R, G, D) (U- ) and animal survival was monitored as a
function of time.
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Table III Effect of anti-asialo GM1 sernm, 2-chloroadenosine or carrageenan on
poly(RGD)-mediated inhibition ofexperimental tumour metastasis
No. oflung metastases
on day 14
Treatment ofmice Poly(RGD) mean ± s.d. (range) pa
None - 119 + 16 (101-138)
+ 57 7( 48- 65) <0.001
Anti-asialo GM1 20 1l i.v. - 144 + 17 (124-164)
+ 59 14( 44- 76) <0.001
2-chloroadenosine 50jig i.v. - 345 ± 28 (302-370)
+ 21± 5 ( 18- 27) <0.001
Carrageenan 1.2 mg i.p. - 332 ± 20 (304-352)
+ 39 14(25- 58) <0.001
B16-BL6melanomacells(5 x 104)wereinjected i.v. with orwithout 100 iLgpoly(RGD)
into groups ofcontrol C57BL/6 mice or mice pretreated 24 h earlier with the indicated
agents or antiserum. Lung tumour colonies were determined 14 days after tumour
inoculation. aCompared with its respective untreated control (PBS) by Student's
two-tailed t test.
Binding capacity (no. of cells bound per substrate) (x 103)
Co-incubation with: 0 5 10
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Figure 2 Effect of platelets and/or poly(RGD) on the adhesion of B16-BL6 cells to fibronectin-coated substrates. '25I-IUdR-
(2 x 104) were added to the wells coated with 5 ggml1' fibronectin in the presence or absence of platelets (5 x I05gl-1) and/or
100 Iygm1' poly(RGD), and incubated at 37C for 10min.
poly(R, G, D), in which three amino acids are randomly
arranged, was not able to suppress the aggregation. Typical
heterotypic cell aggregations between B16-BL6 cells and
platelets, or the aggregation between platelets themselves,
were microscopically observed after their co-incubation for
30 min (Saiki et al., 1989 a). The cell aggregations were
completely inhibited by the addition of 200 gig ml-'
poly(RGD) but not by the addition of poly(R, G, D). These
results clearly indicated that the adhesive interactions
between tumour cells and platelets or between platelets on
their own were completely inhibited by poly(RGD).
Organ localisation and retention ofB16-BL6 melanoma cells
co-injected with poly(RGD)
To investigate the mechanisms responsible for a core
sequence(RGD)-mediated inhibition of tumour colonisation,
we tested the organ distribution and retention of '251-IUdR-
labelled tumour cells to see whether or not the co-injection of
B16-BL6 melanoma cells with poly(RGD) can lead to a
decrease in the arrest of tumour cells in the capillary bed of
the chosen organ. Mice were killed at various times after the
co-injection, and their visceral organs were collected and
monitored for radioactivity in a gamma counter. The data of
a representative experiment (one of three) are shown in Table
IV. Significantly lower values were found in the lungs ofmice
at 4 and 24 h after the co-injection with poly(RGD). How-
ever, there are no discernible differences between control and
poly(RGD) injected mice in the arrest and retention of
labelled tumour cells in liver, spleen, kidneys and blood after
tumour injection (data not shown).
Clearance of'25"-labelledpolypeptide
We recently found that the clearance of '251I-labelled
poly(RGD, K) in the circulation was biphasic and rapid at
an early phase after the i.v. injection (Saiki et al., 1989 b).
We next investigated the possibility that the polypeptide can
be decomposed to by-products in the circulation. Figure 4
shows the separation patterns of the polypeptide by
chromatography. Analysis of the column eluate revealed a
main peak of radioactivity of untreated '251I-labelled
poly(RGD, K) in the void volume. This main peak of 125I-
labelled polypeptide was observed to decrease as a result of
either the treatment with 75% fresh mouse serum or
I mgml-' pronase, and a new broad peak generated around
the fraction number 27. In contrast, polypeptide treated with
heat (56°C, 30 min) inactivated serum showed a similar
-: X.
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Figure 3 Inhibition of tumour-induced platelet aggregation by
polypeptides. Heparinised PRP (5 x I0 Al-') at a volume of
2501jl was treated with PBS (a), poly(R, G, D) (b, 100 sgml-')
and poly(RGD) (c, 100itgml-') 7 min before the addition of
B16-BL6 melanoma cells (t, 106 ml ).
eluting pattern to untreated polypeptide. This result indicates
that '251I-labelled polypeptide can be decomposed into small
molecular weight fragments by a serum or pronase treatment
in vitro.
Discussion
Since the adhesive interactions between tumour cells and
host cells or components of extracellular matrix play a
crucial role in the progress of tumour metastases throughout
a series of complex events, several attempts have been made
to control the mechanisms involved in tumour cell adhesion
during the metastatic cascade. In a previous report (Barsky et
al., 1984), the co-injection of tumour cells with purified
laminin followed by i.v. injection enhanced pulmonary
metastasis, whereas an enzymatic fragment of laminin
inhibited the metastasis. Recently, synthetic oligopeptides
containing characteristic sequences in cell-binding domains of
adhesion molecules (GRGDS derived from fibronectin (Hum-
phries et al., 1986, 1988) or YIGSR derived from laminin
(Iwamoto et al., 1987)) have been shown to inhibit lung
metastases when co-injected i.v. with metastatic tumour cells.
We have synthesised some original polypeptides consisting of
the repetitive structure of a common core sequence in cell
adhesion molecules, such as poly(RGD) or poly(YIGSR),
and found that these polypeptides are able to inhibit experi-
mental lung metastases of B16-BL6 melanoma cells more
effectively than such oligopeptides as RGD, RGDS or
YIGSR on a weight basis (Saiki et al., 1989 c). Furthermore,
intratumoural or intravenous administrations of poly(RGD)
into tumour-beaning mice (in a spontaneous metastasis
model) resulted in a striking reduction of lung tumour col-
onies (Saiki et al., 1989 b).
To extend our previous work on the inhibition of lung
metastasis of tumour cells by a polypeptide containing RGD
sequence, we here examine the inhibitory effect of the
polypeptides on lung metastasis of tumour cells and their
biological characterisation after the administration. Multiple
i.v. administrations of poly(RGD), poly(YIGSR) or their
hybrid polypeptide copoly (RGD, YIGSR) resulted in the
reduction of lung tumour colonies (Table II), but did not
affect the primary tumour size at the time of tumour excision
(data not shown). The co-injection of B16-BL6 melanoma
cells with poly(RGD) significantly enhanced the survival rate
as compared with untreated control, poly(R, G, D) or RGD
(Figure 1). These results indicate that derivatives of RGD-
and/or YIGSR-containing polypeptides may be potentially
useful in the prevention of cancer metastasis.
Once in circulation, metastatic tumour cells encounter
various host cells or components (Fidler, 1984). Metastasis-
ing tumour cells, because of their adhesive properties,
interact with host cells such as lymphocytes, NK cells and
monocytes which are believed to be particularly important in
killing these tumour cells, thus implying that the bloodstream
may provide an inhospitable environment for the circulating
tumour cells. In contrast, platelets have been reported to
enhance the metastatic dissemination of tumour cells at
several of the metastatic stages (Pearlstein et al., 1980). The
adhesive interaction between tumour cells and/or platelets
may form homotypic or heterotypic cell clumps and aggrega-
tions which can subsequently be arrested and extravasated
(Terranova et al., 1982, 1984). Such interactions may also
lead to an enhancement and stabilisation of tumour cell
arrest in capillary vessels by increasing the size of tumour cell
emboli as well as by shielding the tumour cells from immune
response. As shown in Figure 3, tumour-induced platelet
aggregation was completely inhibited by adding poly(RGD)
but not by unrelated random polypeptide, poly(R, G, D). In
addition, poly(RGD) also inhibited the adhesion of B16-BL6
cells to fibronectin-coated substrate (Figure 2). We have
recently reported that the peptides or polypeptides containing
the RGD sequence, when added freely in solution, are able
to inhibit the tumour cell adhesion to fibronectin substrate,
while unrelated peptides such as Arg-Gly-Glu-Ser (RGES) or
His-Gly-Gly (HGG) are not able to do this (Saiki et al., 1989
b). These results clearly demonstrate that the cell adhesion-
inhibiting activities of poly(RGD) depend on a specific
Table IV Lung retention of '25-IUdR-labelled B16-BL6 melanoma cells co-injected
with poly(RGD) into C57BL/6 mice
Radioactivity in lungs (c.p.m. ± s.d.)"
Treatmenta
O.5h 4h 24h
PBS 6528 ± 1604 (42.6%)C 2034 + 284 (13.2%) 498 ± 51 (3.2%)
Poly(RGD) 8723 ± 1850 (56.9%) 1121 + 281 ( 7.3%)d 45 + 19 (0.3%)c
a125I-IUdR-labelled B16-BL6 cells (2 x 104 per mouse) were injected with or without
500lsgpoly(RGD) into the lateral tail vein ofC57BL/6mice. At the indicatedtimes, mice
werekilledandradioactiveelementsretainedinthelungweremeasured.bResults are mean
c.p.m. ± s.d. ofthree mice per group. cParentheses represent % radioactivity oftheinput
(15308 ± 1605c.p.m. per2 x 104cells).dp <0.02,ep <0.001 ascomparedwithuntreated
control (PBS) by Student's two-tailed t test.
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Figure 4 Gel chromatography of '25I-labelled poly (RGD, K) treated with mouse serum or pronase. '251-labelled poly (RGD, K)
(10 lg) was treated with MEM medium (0-0), 75% fresh serum in MEM (0-0) or 75% heat (56'C, 30min)-inactivated
serum in MEM (+ -+) for 16 h, or with I mg ml-' pronase in MEM for 3 h ( -9), and then applied to a column of Sephadex
G-25 eluted with 0.05 M phosphate buffer (pH 7.5) containing 0.25% (w/v) gelatin. Fractions of 70IAl were collected and analysed
for radioactivity. Arrows represent the peaks of VO and '251-IUdR (mol.wt 352) respectively.
mechanism mediated by the RGD core sequence. This also
suggests that tumour cells possess RGD-directed receptors on
their surface (Cheresh et al., 1987; Wewer et al., 1987).
Tumour cell adhesion to fibronectin was enhanced remark-
ably in the presence of platelets (Figure 2). It has been
reported that the mechanism by which platelets enhance
tumour cell adhesion to the subendothelial matrix is
mediated by surface contact between tumour cells and
platelets, and depends on a platelet membrane component
and cytoskeleton (Menter et al., 1987). During the metastatic
process, tumour-induced platelet aggregation may provide an
additional means of adhesion through the interaction of
platelets with adhesion proteins such as fibrinogen and
fibronectin, as well as the opportunity to consolidate the
adhesion through a thrombotic formation caused by platelet
activation and the deposition of fibrin. Poly(RGD) complete-
ly inhibited the platelet-enhanced adhesion of B16-BL6 cells
to the fibronectin substrate (Figure 2). RGD-containing pep-
tides have been shown to inhibit the interaction of adhesive
protein such as fibrinogen, fibronectin and the von Willeb-
rand factor with a platelet membrane, presumably by means
of the glycoprotein complex Ilb/Illa which serves as a recep-
tor on platelets for such adhesive proteins (Haverstick et al.,
1985; Plow et al.,1987). A lIb/Illa-like-glycoprotein identified
on endothelial cells may also serve as a matrix receptor
(Charo et al., 1986; Fitzgerald et al., 1985). Thus the inhibi-
tion of platelet aggregation and platelet-enhanced tumour cell
adhesion to fibronectin substrate by poly(RGD) strongly
implicates that the RGD sequence competitively blocks any
interaction between tumour cells, tumour-stimulated platelets
(presumably the lIb/Illa complex) and such adhesive proteins
as fibrinogen and fibronectin. Further studies will be needed
to determine these points.
To investigate the effect of poly(RGD) on the arrest and
lodgement of tumour cells in organs, we examined the organ
retention of radiolabelled B16-BL6 cells. The co-injection of
the tumour cells with poly(RGD) led significantly to a
reduced arrest of tumour cells in the lung at 4 and 24 h after
the injection (Table IV). The inhibition of lung colonisation
by poly(RGD) may therefore depend on the decrease in the
arrest and retention of tumour cells in the lung as a result of
the inhibition of the adhesive interaction. We recently
reported that radiolabelled polypeptide was biphasically
cleared out from the circulation by the i.v. injection. The
respective half-life of polypeptide at early and late phase was
approximately 15min and 6h (Saiki et al., 1989 b). These
results indicate that this polypeptide may promote cell loss
from the lung over 24 h after the co-injection with tumour
cells.
Poly(RGD) significantly inhibited the experimental lung
metastasis in mice pretreated with anti-asialo GM1 serum,
2-chloroadenosine or carrageenan as well as untreated mice
(Table III). Since poly(RGD) was still active when the cont-
ributions of NK cells and macrophages were removed from
our system, its inhibitory mechanism is likely to be unrelated
to the stimulation and activation of these cells. The
poly(RGD) used did not affect direct cytotoxicity against a
variety of cell, nor did it affect their cell growth and the
aggregation of serum proteins (unpublished data).
In conclusion, we here indicate that a unique RGD-
containing polypeptide can dramatically inhibit lung meta-
stases in experimental and spontaneous metastases models by
means of its ability to interfere with the cellular adhesive
process of metastases. The survival rate of mice receiving
tumour cells admixed with poly(RGD) was virtually
enhanced relative to control groups. Poly(RGD) inhibited the
ability of platelets to enhance the adhesion of tumour cells,
and also led to a decrease in the arrest and retention of
tumour cells in the lung after co-injection with tumour cells.
A polypeptide containing a core sequence derived from cell
adhesion molecules may thus provide a promising approach
for a therapy in the control of cancer metastases.
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